Deutsche Bank cut shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, The Fly reports.
Shares of OTCMKTS BIOVF opened at $20.35 on Thursday.
Swedish Orphan Biovitrum AB (publ) Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Featured Article: Why do corrections happen?
Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.